MyoKardia, Inc (acquired by BMS)
1000 Sierra Point Parkway
Brisbane, CA 94005
United States
Tel: 650-741-0900
Website: http://www.myokardia.com/
Email: info@myokardia.com
About MyoKardia, Inc (acquired by BMS)
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science. MyoKardia is a clinical-stage bio pharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases. The company is pioneering a precision medicine approach to its discovery and development efforts by 1) understanding the bio mechanical underpinnings of disease; 2) targeting the proteins that modulate a given condition; 3) identifying patient populations with shared disease characteristics; and 4) applying learnings from research and clinical studies to inform and guide pipeline growth and product advancement. MyoKardia’s initial focus is on small molecule therapeutics aimed at the proteins of the heart that modulate cardiac muscle contraction to address diseases driven by excessive contraction, impaired relaxation, or insufficient contraction. Among its discoveries are three clinical-stage therapeutics: mavacamten (formerly MYK-461); danicamtiv (formerly MYK-491) and MYK-224. Founded in September 2012 MyoKardia is headquartered in Brisbane, CA.
126 articles about MyoKardia, Inc (acquired by BMS)
-
MyoKardia Announces Proposed Public Offering of Common Stock May 21
5/21/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering of 3,750,000 shares of its common stock.
-
MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy
5/21/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the design of its pivotal Phase 3 EXPLORER-HCM clinical trial to evaluate the use of mavacamten for the potential treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
-
MyoKardia to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
5/10/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 15, 2018, at 11:20 a.m. PT (2:20 p.m. ET) in Las Vegas, NV.
-
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
5/10/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the start of the PIONEER open-label extension (OLE) study of its investigational drug, mavacamten.
-
MyoKardia to Report First Quarter 2018 Financial Results on Tuesday, May 8, 2018
5/8/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report first quarter 2018 financial and operating results after the U.S. financial markets close on Tuesday, May 8, 2018. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).
-
MyoKardia Reports First Quarter 2018 Financial Results
5/8/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported financial results for the quarter ended March 31, 2018.
-
MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer
4/4/2018
MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the appointment of Taylor C. Harris as Chief Financial Officer. Mr. Harris brings more than 20 years of finance and life science industry experience to MyoKardia and will lead the finance, accounting, information technology, facilities, corporate communications and investor relations functions.
-
MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
4/2/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that the first patient has been dosed in the company’s Phase 2 MAVERICK-HCM clinical trial.
-
MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
3/11/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced positive results from the Phase 2 PIONEER-HCM clinical study of the investigational agent mavacamten in symptomatic, obstructive hypertrophic cardiomyopathy (oHCM) patients, including results from a low-dose patient cohort (“Cohort B”), which studied once-daily 2mg and 5mg oral doses of mavacamten.
-
MyoKardia Inc. revealed positive results from a mid-stage obstructive hypertrophic cardiomyopathy trial.
-
MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018
3/8/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report fourth quarter and full year 2017 financial and operating results after the U.S. financial markets close on Thursday, March 8, 2018.
-
MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018
3/8/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that it will report fourth quarter and full year 2017 financial and operating results after the U.S. financial markets close on Thursday, March 8, 2018.
-
MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results
3/8/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017.
-
MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference
3/3/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, will present at the Cowen and Company 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 9:20 a.m. ET in Boston, MA.
-
MyoKardia to Present at the RBC Capital Markets’ 2018 Healthcare Conference
2/14/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that senior management will participate in a fireside chat at the RBC Capital Markets’ 2018 Healthcare Conference on Wednesday, February 21, 2018, at 8:30 a.m. ET in New York, NY.
-
MyoKardia Begins Patient Dosing in Phase Ib Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
2/14/2018
MYK-491 is being developed in an ongoing collaboration between MyoKardia and Sanofi for the treatment of patients with dilated cardiomyopathy.
-
MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients
2/14/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that dosing has commenced in a Phase 1b single-ascending dose patient study of its investigational drug candidate MYK-491.
-
MyoKardia Announces Appointment of Cynthia Ladd as General Counsel
1/19/2018
Ms. Ladd joins MyoKardia having most recently served as senior vice president and general counsel for CytomX Therapeutics, Inc.
-
MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference
1/3/2018
MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference
-
Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
11/15/2017
Data from MyoKardia’s in vivo study demonstrated that treatment with mavacamten improved myocardial compliance while preserving systemic pressures.